Richo and Jones interviews Clive Palmer; thanks him for his generous hydroxychloroquine donation to the nation
Watch the video“Clive, we’re very grateful.” In an interview with Clive Palmer, Alan Jones teases
29/04/2020 9:11 pm
Latest News
Hydroxychloroquine
Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting
Our investigation of a large national cohort appears to support early administration (within the first 3 to 7 days of COVID-19 diagnosis) of HCQ in mild COVID-19 disease in an outpatient setting for reducing hospitalizations and deaths without any serious adverse HCQ-related effects.
If this finding is confirmed in future clinical trials, HCQ as a cheap and available drug may still play a role in a specific population with respect to reducing COVID-19 burden, particularly in resource-poor countries.
06/04/2021
Argentina
A RANDOMIZED TRIAL – INTENSIVE TREATMENT BASED IN IVERMECTIN AND IOTA-CARRAGEENAN AS PRE-EXPOSURE PROPHYLAXIS FOR COVID- 19 IN HEALTHCARE AGENTS
The purpose of this study was to assess the effect of oral Ivermectin treatment, which has been associated with iota-carrageenan in repeated doses through the nasal and oral topical route, on the appearance and eventual progression of COVID-19 disease in a healthy population that are exposed to it and have a higher risk of contagion of SARS-COV-2 for being health personnel from
30/03/2021
Argentina
Ivermectin for Prevention and Treatment of COVID-19 Infection: a Systematic Review and Meta-analysis
Reductions in covid-19 deaths and infections may be possible by using ivermectin. Employing ivermectin early on may reduce the number of people progressing to severe disease. The apparent safety and low cost suggest that ivermectin could have an impact on the SARS-CoV-2 pandemic globally.
18/03/2021
Hydroxychloroquine
Structural basis of anti-SARS-CoV-2 activity of hydroxychloroquine: specific binding to NTD/CTD and disruption of LLPS of N protein
In this study, by use of DIC microscopy and NMR spectroscopy, for the first time we have decoded that HCQ specifically binds to both N-terminal domain (NTD) and C-terminal domain (CTD) of SARS-CoV-2 nucleocapsid (N) protein to inhibit their interactions with nucleic acids (NAs), as well as to disrupt its NA-induced liquid-liquid phase separation (LLPS) essential for the viral life cycle including the package of gRNA and N protein into new virions.
17/03/2021
Australia
Covid-19 vaccine concerns: Clive Palmer
Source: The Palmer Foundation Men and Women of Australia I feel duty bound to bring
11/03/2021
India
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study
We conclude that two-dose ivermectin prophylaxis at a dose of 300 μg/kg body weight with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among HCWs in the following one month. Chemoprophylaxis has relevance in the containment of pandemic. This is an intervention worth replicating at other centers until a vaccine is widely available.
16/02/2021
Azithromycin
Effectiveness of multidrug therapy including ivermectin, to prevent hospitalization and death among ambulatory COVID-19 cases – Mexico
•TNR4 is a multidrug therapy (Ivermectin, Azithromycin, Montelukast and ASA) for COVID-19 cases.
•TNR4 increased the likelihood of recovery 3.4 times in ambulatory COVID-19 cases.
•The multidrug therapy TNR4 reduced the risk of hospitalization by 75%.
•The multidrug therapy TNR4 reduced the risk of death by 81%.
10/02/2021
Hydroxychloroquine
Phase 1 Randomized Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate – A Potential Treatment for COVID-19
We tested the hypothesis that aerosolized HCQ sulfate (aHCQ) tolerably, safely, and rapidly achieves high respiratory tissue concentrations, while minimizing systemic toxicity.
01/02/2021
Hydroxychloroquine
HCQ Peer-reviewed: Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection
American Journal of Medicine announces peer-reviewed early outpatient treatment protocol for Covid19 including hydroxychloroquine. Acute COVID-19 has a great range of clinical severity from asymptomatic to fatal. In the absence of clinical trials and guidelines, with hospitalizations and mortality mounting, it is prudent to deploy treatment for COVID-19 based on pathophysiological principles.
30/01/2021
Africa
Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19 infection includes HCQ & Ivermectin
Source: Reviews in Cardiovascular Medicine Peter A. McCullough, Paul E. Alexander, Robin Armstrong, Cristian Arvinte,
28/01/2021
Africa
Ivermectin for Covid-19: Database of all Ivermectin COVID-19 studies – 35 trials and growing
Source: ivmmeta.com Figure 1. A. Random effects meta-analysis excluding late treatment. Simplified dosages are shown for comparison,
27/01/2021
Clinical Trials
Use of Ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt : A randomised clinical trial
Source: Research Gate SHOUMAN WM1, HEGAZY AA2, NAFAE RM3, RAGAB ME4, SAMRA SR5, ANAS D6,
25/01/2021
Hydroxychloroquine
Nebulized Hydroxychloroquine for COVID-19 Treatment: 80x Improvement in Breathing – Dr Vladimir Zelenko
Based on this real world experience and data, nebulized hydroxychloroquine significantly improves patient outcomes and should be considered as part of the armamentaria against Covid-19.
24/01/2021
Azithromycin
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study
In this study of COVID-19, for infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization
14/01/2021
Clinical Trials
The results of a meta-analysis of 187 studies treating COVID-19 successfully with hydroxychloroquine are statistically irrefutable.
HCQ is effective for COVID-19. The chance that an ineffective treatment generated results as positive as the 187 studies to date is 1 in 5 quadrillion (p = 0.00000000000000019).
05/01/2021
Hydroxychloroquine
Higher Hydroxychloroquine Blood Levels Are Associated with Reduced Thrombosis Risk in Systemic Lupus Erythematosus
Source: PubMed Petri M, Konig MF, Li J, Goldman DW. Higher Hydroxychloroquine Blood Levels Are
05/01/2021
France
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
Hydroxychloroquine is an effective molecule against COVID-19 infection, many RCTs and observational studies, affirmed the benefits on virological clearance.
04/01/2021
Azithromycin
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19
No cases of sudden death were observed. From publication, we have treated 3,119 patients with HCQ-AZ for at least three days.
04/01/2021
Azithromycin
Top US medics recommend ‘sequenced multidrug therapy’ including HCQ & Ivermectin, for early high-risk COVID-19 infections
Early SMDT (sequenced multidrug therapy) should be a standard practice in high risk & severely symptomatic acute COVID-19 patients at the onset of illness.
30/12/2020
Hydroxychloroquine
Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation; the experience from Shanghai, China
The early use of
hydroxychloroquine decreased the improvement time
and the duration of COVID-19 detection in throat and
stool swabs.
18/12/2020
Australia
TGA banned a functioning treatment & Australian doctors want answers – Urgent request for revocation of HCQ ban
Adjunct Prof John SkerrittDeputy SecretaryHealth Products Regulation GroupJohn.Skerritt@health.gov.auGPO Box 9848, Canberra, ACT Dear Professor Skerritt,We
15/12/2020
Africa
A massive hydroxychloroquine meta-analysis (156 studies) has just been updated (version 28!).It says that HCQ works beyond all statistical doubt.
Source: HCQMeta.com HCQ is effective for COVID-19 when used early: meta-analysis of 156 studies (Version
05/12/2020
Clinical Trials
Low Dose Hydroxychloroquine is Associated with Lower Mortality in COVID-19: A Meta-Analysis of 27 Studies and 44,684 Patients
Source: Research Square. Methods This study was conducted according to the recommendations outlined in the
02/12/2020
Australia
Effective post-exposure prophylaxis of Covid-19 is associated with use of HCQ: Prospective re-analysis of a public dataset incorporating novel data
Source: MedRxIV David M. Wiseman, Pierre Kory, Samir A Saidi, Dan Mazzucco doi: https://doi.org/10.1101/2020.11.29.20235218 Abstract BACKGROUND A recent trial (NCT04308668) found that post-exposure
02/12/2020
Azithromycin
A Guide to Home-Based COVID Treatment -A Step-By-Step Doctors’ Plan That Could Save Your Life
Source: AAPS Online Senior Editor:Jane Orient, MD, Internal Medicine Physician, Executive Director,Association of American Physicians
18/11/2020
Azithromycin
HCQ Protocols from America’s Frontline Doctors
Source: America’s Frontline Doctors THIS IS NOT MEDICAL ADVICE. Every situation is unique, and every
17/11/2020
Azithromycin
Swiss Policy Research on the Treatment of Covid-19
Source: swprs.org On the Treatment of Covid-19 Updated: November 16, 2020; Published: July 2, 2020 Immunological
16/11/2020
Belgium
In 2003, the effects of chloroquine/HCQ on viral infections were known: an old drug pitted against SARS and HIV
Results obtained in the prophylaxis of Q fever indicate that chloroquine/hydroxychloroquine can be successfully used in the clinical management of infections other than malaria.
14/11/2020
Azithromycin
Prevalence of Diabetes, Management and Outcomes among Covid-19 Patients; HCQ protects from Covid-19 death by 88%: Saudi Arabia
Source: Science Direct Eman Sheshah, Shaun Sabico, Rashed M. Albakr, Anmar A. Sultan, Khalaf S.
13/11/2020
Bulgaria
Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health care workers: Bulgaria
Source: Science Direct Simova I, Vekov T, Krasnaliev J, Kornovski V, Bozhinov P,Hydroxychloroquine for prophylaxis
12/11/2020
Clinical Trials
Hydroxychloroquine Not Linked to Longer Heart Rhythm Intervals in Rheumatoid Arthritis or Lupus Patients
Of the whole study group (RA and SLE), 54% used hydroxychloroquine and 44% had QTc lengths of more than 440 milliseconds. They found that the adjusted QTc length among hydroxychloroquine users was comparable to those who did not use the drug.
06/11/2020
Hydroxychloroquine
Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 in health-care workers: A single-center experience
Source: Journal of Marine Medical Society Date of Submission 23-Aug-2020 Date of Decision 18-Sep-2020 Date
06/11/2020
Clinical Trials
India: Post Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the Prevention of COVID-19, a Myth or a Reality? The PEP-CQ Study
Source: Science Direct Dr. Deba PrasadDhibarMD(Assistant Professor)aDr. NavneetAroraMD(Senior Resident)aDr. ArpitKakkarDNB(Senior Resident)aDr. NeerajSinglaMD(Assistant Professor)bDr. RitinMohindraMD(Assistant Professor)bDr.
06/11/2020
Azithromycin
Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients
Figure 3 reported random forest for 10 studies comparing HCQ+AZM. Use of the combination HCQ+AZM was associated with 25% lower mortality risk
04/11/2020
Hydroxychloroquine
Inhalable liposomal hydroxychloroquine (TLC19) may provide clinical benefit and serve as a potential treatment for COVID-19: Taiwan & California
Source: BioSpace SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 03, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq:
03/11/2020
Africa
HCQ is effective for COVID-19 when used early: analysis of 132 studies
Source: HCQmeta.com • HCQ is effective for COVID-19. The probability that an ineffective treatment generated
02/11/2020
Azithromycin
COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study
This means that zinc, low dose HCQ, and azithromycin and may prevent a large number of hospitalizations and probably deaths during the SARS-CoV-2 pandemic.
26/10/2020
Azithromycin
Clinical Characteristics and Prognosis of COPD Patients Hospitalized with SARS-CoV-2
We found a higher survival rate in patients treated with hydroxychloroquine and with macrolides in our study.
26/10/2020
Azithromycin
Outcomes of patients with COVID-19 in the Intensive Care Unit in Mexico: A multicenter observational study
This study of critically ill patients with laboratory-confirmed COVID-19 admitted to ICUs in Mexico demonstrated that age and CRP levels upon ICU admission were associated with in-hospital mortality
21/10/2020
A Doctor's Story
Choose Truth and Choose Life
Author: Vladimir Zev Zelenko M.D. Source Truth stands the test of time. We are currently
20/10/2020
Azithromycin
Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia
Our results can assure that hydroxychloroquine used for COVID-19 patients is safe, highly tolerable, and with minimum side effects.
17/10/2020
Chloroquine
Hydroxychloroquine linked to reducing ICU admissions among hospitalized COVID-19 patients by 53%
Hydroxychloroquine, however, was associated with a 53% reduction of being transferred to the ICU.
15/10/2020
Ivermectin
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID19 Study
Ivermectin treatment was associated with lower mortality during treatment of COVID-19, especially in patients with severe pulmonary involvement.
13/10/2020
Azithromycin
Hydroxychloroquine is effective, and consistently so used early, for Covid-19: A systematic review
HCQ has greater efficacy if given earlier in the course of the disease. Several negative studies have been withdrawn due to methodological improprieties.
09/10/2020
Australia
Australian MP’s Open Letter to Dr Jeannette Young – Queensland Chief Health Officer ( Hydroxychloroquine )
Australian MPs censored for presenting science. AUSTRALIA: North Queensland MP George Christensen, and the Member
30/09/2020
Hydroxychloroquine
The Netherlands study: Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients
Source: Science Direct A.J.J.LammersaR.M.BrohetbR.E.P.TheunissenaC.KosteraR.RoodcD.W.M.VerhagendK.BrinkmaneR.J.HassingfA.DofferhoffgR.el MoussaouihG.HermanidesiJ.EllerbroekjN.BokhizzoukH.VisserlM.van den BergemH.BaxnD.F.PostmaoP.H.P.Groenevelda aIsala, Zwolle, The NetherlandsbDepartment of Epidemiology and Statistics,
29/09/2020
Hydroxychloroquine
Spain/US – Brief communication: A meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19 (HCQ reduces the risk of COVID-19 by about 20%)
Source: MedRxiv. Full Study in PDF here Xabier Garcia-Albeniz, Julia Del Amo, Rosa Polo, Jose Miguel Morales Asencio, Miguel A HernanmedRxiv 2020.09.29.20203869; doi: https://doi.org/10.1101/2020.09.29.20203869 Abstract Background: There
29/09/2020
Global
C19study.com update: Now 118 international studies (71 peer reviewed) show positive hydroxychloroquine treatment outcomes
Source: C19Study A live and ongoing index of studies from around the world documenting the use
28/09/2020
Azithromycin
Italy study: A new look at safety with hydroxychloroquine in COVID-19
In our study, we found hydroxychloroquine wasn’t associated with significant arrhythmia clearly relating to hydroxychloroquine so it seemed the drug was very, very safe
28/09/2020
Azithromycin
Saudi Arabia – Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm
Therefore, Hydroxychloroquine is considered as the first‐line of COVID-19 treatment.
22/09/2020
Azithromycin
Lancet: “Overall mortality was lower in the hydroxychloroquine group”. Study, Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study
Source: The Lancet Summary Background Hydroxychloroquine is one of several agents being evaluated in the
21/09/2020
Azithromycin
University of Minnesota study: “No deaths occurred related to hydroxychloroquine. ” Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19
In this trial, no deaths occurred related to hydroxychloroquine, and serious side effects were rare.
21/09/2020
Chloroquine
HYDROXYCHLOROQUINE AND THE BURDEN OF PROOF
An Urgent Call to Depoliticize Medicine in the COVID-19 Pandemic
20/09/2020
Azithromycin
Ghana: “HCQ and AZ associated with viral clearance in COVID-19 patients.” Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study
HCQ or CQ should be used efficiently alone or in combination with AZ to optimize the management of asymptomatic and mild cases of COVID-19.
15/09/2020
Hydroxychloroquine
COVID-19 is a lack of nutrients, exploited by a virus
Source: Primary Doctor Author: Colleen Huber, NMD Abstract COVID-19 disease is alleged to be caused
07/09/2020
Clinical Trials
Hydroxychloroquine is Effective and Safe for the Treatment of COVID-19, and May be Universally Effective When Used Early Before Hospitalization: A Systematic Review
Source: Research Gate Conclusions Hydroxychloroquine has been shown to have consistent clinical efficacy for COVID-19
04/09/2020
Azithromycin
Spain – 1766P COVID-19 and lung cancer: What do we know?
There seems to be a trend towards lower mortality among patients who received treatment with the combination of hydroxychloroquine and azithromycin than among those who did not
01/09/2020
Belgium
A simple and clear explanation of recent positive and negative studies: hydroxychloroquine has strong evidence of efficacy, by Dr John Campbell
Dr. John Campbell Belgium, not Dutch. Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with
28/08/2020
Hydroxychloroquine
New Jersey Study of 1,274: Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19; A multi-center observational study where hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization
In this study, SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization.
25/08/2020
Azithromycin
Italy Study 3,451 patients: Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study
HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Our data doesn’t discourage use of HCQ in inpatients with COVID-19.
25/08/2020
Belgium
Belgium Study: Low-dose Hydroxychloroquine Therapy and Mortality (Lowered) in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants
Source: Science Direct Authors: LucyCatteauPharmD, PhDafi#NicolasDaubyMD, PhDbcdfi#MarionMontourcyMScafiEmmanuelBottieauMD, PhDefiJorisHautekietMScagfiElsGoetghebeurPhDfigSabrinavan IersselMD, PhDfihElsDuysburghMD, MPH, PhDafiHermanVan OyenMD, DrPHafhiChloéWyndham-ThomasMD, PhDafiDominiqueVan
24/08/2020
Australia
Australia: Clinical trial looks to protect high-risk healthcare workers against COVID-19 using hydroxychloroquine as preventative to corona
Source: St Vincent’s Hospital Melbourne Healthcare workers are part of the first line of defence
21/08/2020
Azithromycin
Mortality 0%: A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island
Indeed, following bivariate analysis, hydroxychloroquine/azithromycin treatment was associated with a lower rate of ICU admission (P=0.008).
20/08/2020
Hydroxychloroquine
Possible role of ABCB1 in lysosomal accumulation of azithromycin in COVID-19 therapy
Source: PubMed. Author: Jean-Michel Scherrmann Scherrmann JM. Possible role of ABCB1 in lysosomal accumulation of
17/08/2020
Hydroxychloroquine
Pandemic: National Town Hall, The Case for Hydroxy Pt.1 (w/ Dr. Harvey Risch, Dr. Vladimir Zelenko, and Dr. Li Meng Yan)
Source: Pandemic War room Jack Maxey and Vish Burra bring you a special edition of
09/08/2020
Censorship
Henry Ford Health Defends Study, Shows Hydroxychloroquine Does Reduce Death Rates
Source: CBS Detroit (CBS DETROIT) – Henry Ford Health System is defending its hydroxychloroquine study showing
04/08/2020
China
China Study of 2882 patients: Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs
HCQ treatment can reduce systemic inflammation and inhibit the cytokine storm, thus protecting multiple organs from inflammatory injuries.
03/08/2020
Hydroxychloroquine
Italian Study: Hydroxychloroquine Cut Death Risk 66 Percent
Source: Newsmax An Italian study found that hospitalized coronavirus patients who took anti-malaria drug hydroxychloroquine combined
02/08/2020
Azithromycin
France Study: Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time
Indeed, our study suggests that AZI±HCQ might have impacted COVID-19 outcome in a population of patients, optimal timing of treatment interventions to study
02/08/2020
Hydroxychloroquine
Italy Study: Effectiveness of Hydroxychloroquine in COVID-19 disease: A done and dusted situation? – 66% reduction in risk of death
hydroxycholoroquine + azithromycin was associated with a 66% reduction in risk of death as compared to controls; the analysis also suggested a larger effectiveness of hydroxychloroquine in patients with less severe COVID-19 disease
29/07/2020
Clinical Trials
61 studies (37 peer reviewed) Early treatment studies are very positive – COVID deaths: 621, 206
Source: c19study.com The studies continue to roll out, and there has been very positive results
23/07/2020
Official
Madrid Study: Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid – Risk of death significantly lower with HCQ
Source: Medrxiv.org In this analysis of 1645 patients hospitalized with COVID-19 we find that the
17/07/2020
Medical Study
South Korea Study: Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
Source: IC Journal Citation: Hong KS, Jang JG, Hur J, Lee JH, Kim HN, Lee
16/07/2020
Hydroxychloroquine
UK Study: Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls
HCQ use significantly reduced the mortality rate, but this association was found only in the lowest cumulative dosage exposure group.
12/07/2020
Azithromycin
Zelenko study: COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin; A Retrospective Case Series Study
Source: preprints.org Scholz, M.; Derwand, R.; Zelenko, V. COVID-19 Outpatients – Early Risk-Stratified Treatment with
04/07/2020
Azithromycin
HENRY FORD STUDY: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19
Source: International Journal of Infectious Diseases Highlights As of May27, 2020 there are over 1,678,843
01/07/2020
Hydroxychloroquine
NY Study: Risk Factors for Mortality in Patients with COVID-19 in New York City
In this study of over 6000 hospitalized patients with COVID-19 in the New York City, hydroxychloroquine use was associated with decreased mortality.
30/06/2020
France
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/ azithromycin and other regimens in Marseille, France: A retrospective analysis
Source: Science Direct Background In our institute in Marseille, France, we initiated early and massive
25/06/2020
Chloroquine
COVID-19: Nigerian study finds Chloroquine, Hydroxychloroquine effective as Prophylaxis
Source: Vanguard Nigeria Preliminary trials on the use of chloroquine and hydroxychloroquine as prophylaxis for
23/06/2020
China
Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of COVID-19 Spike pseudotype virus
Source: BioRxiv The pandemic coronavirus COVID-19 affected global health from the end of 2019 to
22/06/2020
China
Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study
This study provides evidence that (hydroxy)chloroquine may be used effectively in treating moderate COVID-19 and supports larger trials.
22/06/2020
Chloroquine
Denmark: Chloroquine, but not hydroxychloroquine, prolongs the QT interval in a primary care population
Conclusions: In subjects free of COVID-19, we found a small increase in QTc associated with use of chloroquine, but not hydroxychloroquine. We found no increased mortality associated with use of hydroxychloroquine.
22/06/2020
Chloroquine
Study|China- Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study
This study provides evidence that (hydroxy)chloroquine may be used effectively in treating moderate COVID-19 and supports larger trials.
22/06/2020
Clinical Trials
Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France
Significantly higher rates of discharge home were observed in patients treated by HCQ, a novel finding warranting further confirmation in replicative studies.
19/06/2020
Azithromycin
Spain Study: A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with non-severe disease. A strategy associated with a reduction in hospital admissions and complications.
None of the patients died in the studied period and only 6 have to be admitted in conventional hospitalization area.
12/06/2020
Hydroxychloroquine
Study: Strategy – HCQ + AZ treats mild COVID-19 to reduce hospital admissions and complications.
Source: MedRxiv Abstract: The new SARS-CoV-2 infection named COVID-19 has severely hit our Health System.
12/06/2020
Hydroxychloroquine
Study: Pre exposure Hydroxychloroquine use reduces COVID19 risk in healthcare workers
Source: MedRxiv Abstract Background: While several trials are ongoing for treatment of COVID-19, scientific research
12/06/2020
France
Study – Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big data and the real world (19,270 patients – is effective)
Source: ScienceDirect | PDF of full Journal Pre-Print Abstract In the context of the current
06/06/2020
Global
Lancet RETRACTS suspect research study of 96,000, which stated HCQ had no effect. Important win for science.
Preface: On May 22, The Lancet published a study of 96,000 COVID-19 patients stating Hydroxychloroquine
05/06/2020
Clinical Trials
EARLY DIAGNOSIS AND MANAGEMENT OF COVID-19 PATIENTS: A REAL-LIFE COHORT STUDY OF 3,737 PATIENTS, MARSEILLE, FRANCE (HCQ-AZ)
Source: Mediterranee Infection COVID-IHU #15 Version 1 du 27 Mai 2020Early diagnosis and management of COVID-19 patients: a real-life cohort study of 3,737 patients,
28/05/2020
Australia
182 Professionals from 25 countries around the globe raise serious concerns with The Lancet’s anti HCQ report
Source: Zendo In an open letter to MR Mehra, SS Desai, F Ruschitzka, and AN
28/05/2020
Clinical Trials
YALE: Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis (HCQ – AZ)
Source: Oxford Academic – American Journal of Endimology Original unedited manuscript as PDF Abstract More
28/05/2020
Hydroxychloroquine
World renowned Dr leading one of the largest U.S. studies sees hydroxychloroquine promise
Source: FOX 2 – Detroit The FDA has warned against taking hydroxychloroquine, but President Trump says
21/05/2020
Hydroxychloroquine
Adding Zinc to hydroxychloroquine and azithromycin improves odds: 44% less likely to die from COVID-19 (NYU Study of 900).
Source: NY1 NEW YORK – Researchers at NYU’s Grossman School of Medicine found patients given
17/05/2020
Clinical Trials
Peer reviewed; 91.7% good outcomes with early treatment of COVID-19 patients using hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
Source: Science Direct Abstract Background In France, the combination hydroxychloroquine (HCQ) and azithromycin (AZ) is
08/05/2020
China
China study of 568 critically ill Covid-19 patients: Hydroxychloroquine treatment significantly associated with a decreased mortality, through attenuation of inflammatory cytokine storm.
Source: MedRxiv Abstract Importance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs
01/05/2020
Hydroxychloroquine
DRUG TRIAL 2,300 patients; physicians and surgeons (AAPS) say hydroxychloroquine drug DOES help 91% of coronavirus patients
SOURCE: The Sun UKDOCTORS in the US have claimed that a now controversial malaria drug
29/04/2020
Azithromycin
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
Source: Science Direct PhilippeGautretab1Jean-ChristopheLagierac1PhilippeParolaabVan ThuanHoangabdLineMeddebaJacquesSevestreaMorganeMailheaBarbaraDoudieraCamilleAubryaSophieAmraneaPisethSengaMarieHocquartaCaroleEldinabJulieFinanceeVera EstevesVieiraaHervé TissotTissot-DupontacStéphaneHonoréfgAndreasSteinacMatthieuMillionacPhilippeColsonacBernardLa ScolaacVéroniqueVeithAlexisJacquieriJean-ClaudeDeharojMichelDrancourtacPierre EdouardFournierabJean-MarcRolainacPhilippeBrouquiacDidierRaoultac aIHU-Méditerranée Infection, Marseille, France bAix Marseille
11/04/2020
Hydroxychloroquine
Dr. Vladimir Zelenko: Hydroxychloroquine, Zinc Sulfate and Azithromycin are showing excellent results with 900 coronavirus patients treated.
Source: Tech Startups Peak Prosperity April 8 Update: More doctors are now saying Hydroxychloroquine only works
08/04/2020
Australia
More Vaccine Blood Clots – Craig Kelly Backed Up By Medical Specialists Supporting Ivermectin!
In an interview with Alan Jones, Craig Kelly MP discusses the vaccine rollout mishaps and yet again, rightfully points out the myriad of medical specialists around the world who support the use of ivermectin for the prophylaxis and treatment of their Covid-19 patients with the backup of extensive positive data.
16/04/2021
Algeria
The Chloroquine Wars Part XV – How to Rig Research: Surgisphere Part II
It would be a historically amazing feat of maneuvering bureaucracy, worthy of its own epic book, movie, or perhaps a campfire song, to have wrangled that much data out of those hospitals with highly variable regulations and procedures, nearly all of which are in the U.S. healthcare system.
15/04/2021
Ivermectin
American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk
Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.
14/04/2021
A Doctor's Story
Open Letter by U.S. Doctors: JAMA Anti-Ivermectin Study Is Misleading and Fatally Flawed
The severe weaknesses of this study make it uninformative about whether ivermectin is beneficial in early COVID-19 treatment. Yet, the authors misleadingly conclude that their findings “do not support the use of ivermectin for treatment of mild COVID-19”, as if they had enough quality data to make that case, which they do not.
14/04/2021
Global
The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I
It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.
13/04/2021
A Patient Story
Another New York State Supreme Court Justice Ivermectin Order Helping 81-Year-Old Farmer
Ivermectin, a medicine for parasites, has been around for four decades. While not authorized for use against COVID-19, dozens of studies show materially positive results. At well-established human dosage levels, the drug is safe: hundreds of millions of people are treated with it every year mostly in the tropics for various parasite-borne diseases, such as River Blindness in Nigeria.
10/04/2021
Censorship
The Chloroquine Wars Part XIII -A Clockwork Orange Man
Immediately following HCQ’s Trump moment, the media went on an all-out blitz to associate the topic of HCQ with a sense of fear. Fear of Trump, fear of death, fear of incompetence, fear of opposing scientific authorities, fear of using medicine needed by somebody else, and fear of the unknown. And the campaign of fear didn’t stop there.
10/04/2021
Brazil
The Chloroquine Wars Part XII – Manufactured Fear During Hydroxychloroquine’s Trump Moment
The primary effect of the article was likely to further ingrain a partisan association with the subject matter, along with the subtext, “Whatever good SCIENCE exists, it can only be on our side [so you won’t need to think any more about it].”
09/04/2021
Azithromycin
Texas Physician/Researchers Case Series Finds Reduction in COVID-19 Hospitalization by 87.6% & Death 74.9%
The authors emphasize the historically significant & relevant role of empiric treatment in an attempt to reduce death. Doing nothing is not good medicine.
09/04/2021
About The Foundation
The Palmer Foundation is the philanthropic entity owned by the Palmer family, headed by Clive Palmer.
The Palmer Foundation is a private entity that engages in charitable projects that enable better welfare of others, and society as a whole.
The foundations most recent endeavour revolves around the response to, and action on the COVID-19 Virus pandemic for the treatment of all Australians in need.
Click here to get the background on The Palmer Foundations COVID-19 Response.
Share on facebook
Share on twitter
Share on whatsapp
On Trend
Popular Stories
Australia
More Vaccine Blood Clots – Craig Kelly Backed Up By Medical Specialists Supporting Ivermectin!
In an interview with Alan Jones, Craig Kelly MP discusses the vaccine rollout mishaps and yet again, rightfully points out the myriad of medical specialists around the world who support the use of ivermectin for the prophylaxis and treatment of their Covid-19 patients with the backup of extensive positive data.
16/04/2021
Algeria
The Chloroquine Wars Part XV – How to Rig Research: Surgisphere Part II
It would be a historically amazing feat of maneuvering bureaucracy, worthy of its own epic book, movie, or perhaps a campfire song, to have wrangled that much data out of those hospitals with highly variable regulations and procedures, nearly all of which are in the U.S. healthcare system.
15/04/2021
Ivermectin
American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk
Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.
14/04/2021
A Doctor's Story
Open Letter by U.S. Doctors: JAMA Anti-Ivermectin Study Is Misleading and Fatally Flawed
The severe weaknesses of this study make it uninformative about whether ivermectin is beneficial in early COVID-19 treatment. Yet, the authors misleadingly conclude that their findings “do not support the use of ivermectin for treatment of mild COVID-19”, as if they had enough quality data to make that case, which they do not.
14/04/2021